Gastric cancer is a common tumour that represents a number of challenges for both oncologists and surgeons. In Europe and America the incidence appears to be declining overall, with an apparent increase in the proportion of proximal lesions and a decrease in the proportion of distal and antral cancers. Only approximately 20% of patients present with surgically curative disease and the operative mortality rates still remain significant. Overall 5 year survival is approximately 5%, reflecting the high proportion of advanced disease. Survival for curative resections is dependent upon stage (Fielding et al., 1984) . In a large UK series 5 year survival for stage I, II and III disease was 72%, 32% and 10% respectively (Allum et al., 1989) . In Japan extensive lymphadenectomy in addition to excision of the primary lesion is routinely used, however, a survival advantage for this approach is unproven. Currently there are two randomised trials comparing extensive with limited lymph node dissection: one of these is being undertaken by the Medical Research Council (MRC), the other by a group in Holland. Neither of these have reported on their survival results, but the Dutch study of 996 patients resulted in a higher operative mortality rate and complication rate in patients undergoing the more extensive dissection (Bonenkamp et al., 1995) .
There have been a number of randomised trials investigating adjuvant chemotherapy, all of which were small in size and have used less than optimal chemotherapy. A meta-analysis in 1993 of 11 trials and 2096 patients demonstrated no significant benefit in terms of additional survival in patients having adjuvant therapy . However, this report was later criticised for failing to include two eligible trials found in a more exhaustive search of the literature and when these data were included the common odds ratio of 0.82 (95% confidence interval 0.68-0.98) was obtained in favour of the adjuvant chemotherapy group . The meta-analysis did not include two randomised Japanese trials performed before 1980 that used single agent intravenous mitomycin C (Imanaga and Nakazato, 1977; Nakajima et al., 1978) , one of which demonstrated a significant survival advantage in favour of the treatment arm and was the basis for the routine treatment of Japanese patients with adjuvant chemotherapy. More recently, and since the meta-analysis, the adjuvant use of intraperitoneal carbon absorbed mitomycin C in T3 and T4 tumours has shown a highly significant improvement in 3 year survival (Hagiwara et al., 1992 ) and enlargement of a Spanish trial included in the meta-analysis has shown that the survival advantage is maintained in the treatment arm using single agent intravenous mitomycin C (Grau et al., 1993 
